Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
However, results from a phase 2A clinical trial (ClinicalTrial.gov Identifier: NCT01263366) showed significantly reduced radiodermatitis at the site of NG12-1 administration vs control areas within the same radiotherapy field. The average score for dermatitis was 0.47 in the area pretreated with NG12-1 and 0.72 in the untreated control area (P =.022). All 9 patients experienced reduced severity of radiodermatitis in the treatment areas, and no serious adverse events occurred.5
“The limitations of the present pilot phase 2a study include the small number of treated subjects, the lack of blinding between drug-treated and placebo-treated topical sites, and a 50-cm2 SDAS within a much larger chest and axilla radiation field,” noted the authors.5
Conclusions
These results seem to indicate an early but changing tide in the treatment of radiodermatitis. As evidence mounts, clinicians can choose preventive and therapeutic options for their patients.
“Today, there is increasing evidence to support various strategies to limit and treat cutaneous reactions to radiotherapy. To prevent acute radiodermatitis, daily dermocosmetic use is useful from the beginning of radiotherapy,” concluded the authors of one review.
“There is evidence for the efficacy of PBM [LLLT] to both prevent and cure acute radiodermatitis. In chronic radiodermatitis, treatment with vascular lasers, especially pulsed dye laser, using short pulse durations, has been shown to be effective with an excellent tolerance, inducing a better quality of life for the patients.”1
Megan Garlapow is a medical writer based in Tempe, Arizona.
References
1. Seité S, Bensadoun RJ, Mazer JM. Prevention and treatment of acute and chronic radiodermatitis. Breast Cancer (Dove Med Press). 2017;9:551-557.
2. Robijns J, Censabella S, Claes S, et al. Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial) [published online February 10, 2018]. Lasers Surg Med. doi: 10.1002/lsm.22804
3. Chen H, Wu M, Li G, Hua L, Chen S, Huang H. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: a cohort study. Medicine. 2017;96(44):e8202.
4. Haruna F, Lipsett A, Marignol L. Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Anticancer Res. 2017;37(10):5343-5353.
5. Cleary JF, Anderson BM, Eickhoff JC, Khuntia D, Fahl WE. Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor. Radiat Oncol. 2017;12(1):201.
